Difficult to control atopic dermatitis

World Allergy Organization Journal

Volumn 6, Issue 1, 2013, Pages

  Darsow, Ulf ^a   Wollenberg, Andreas ^b   Simon, Dagmar ^c   Taïeb, Alain ^d   Werfel, Thomas ^e   Oranje, Arnold ^f   Gelmetti, Carlo ^g   Svensson, Ake ^h   Deleuran, Mette ⁱ   Calza, Anne Marie ^j   Giusti, Francesca ^k   Lübbe, Jann ^j   Seidenari, Stefania ^k   Ring, Johannes ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF BERN   (Switzerland)

^d HÔPITAL SAINT ANDRÉ   (France)

^e HANNOVER MEDICAL SCHOOL   (Germany)

^f ERASMUS MEDICAL CENTER   (Netherlands)

^g UNIVERSITY OF MILAN   (Italy)

^h LUND UNIVERSITY HOSPITAL   (Sweden)

ⁱ AARHUS UNIVERSITY HOSPITAL   (Denmark)

^j GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^k UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

more..

Author keywords

Atopic dermatitis; Eczema; Guideline; Therapy

Indexed keywords

ALEFACEPT; ANTIHISTAMINIC AGENT; ANTIINFECTIVE AGENT; AZATHIOPRINE; CICLOPIROXOLAMINE; CORTICOSTEROID; CYCLOSPORIN; EFALIZUMAB; EMOLLIENT AGENT; GLUCOCORTICOID; HYDROXYZINE; KETOCONAZOLE; LANOLIN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEOMYCIN; PIMECROLIMUS; RITUXIMAB; TACROLIMUS;

ADJUVANT THERAPY; ANTIINFLAMMATORY ACTIVITY; ATOPIC DERMATITIS; CONTACT ALLERGY; CONTACT SENSITIZATION; COUNSELING; DISEASE CONTROL; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFECT; ECZEMA; HUMAN; MICROBIAL COLONIZATION; PHOTOTHERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PRURITUS; REVIEW; SUPERINFECTION; T LYMPHOCYTE ACTIVATION; THERAPY; ULTRAVIOLET A RADIATION; ULTRAVIOLET IRRADIATION;

EID: 84887835818     PISSN: 19394551     EISSN: None     Source Type: Journal    
DOI: 10.1186/1939-4551-6-6     Document Type: Review

References (45)

1. Ring J, Przybilla B, Ruzicka T (Eds): Handbook of atopic eczema. 2nd edition. Heidelberg: Springer; 2006.
2. Ring J, Alomar A, Bieber T, Deleuran M, Fink-Wagner A, Gelmetti C, Gieler G, Lipozencic J, Luger T, Oranje AP, Schäfer T, Schwennesen T, Seidenari S, Simon D, Ständer S, Stingl G, Szalai S, Szepietowski JC, Werfel T, Wollenberg A, Darsow U: Guidelines for Treatment of Atopic Eczema (Atopic Dermatitis) Part I. J Eur Acad Dermatol Venereol 2012, 26:1045-1060.
3. Manzini BM, Ferdani G, Simonetti V, Donini M, Seidenari S: Contact sensitization in children. Contact Dermatitis 1998, 15:12-17. (Pubitemid 28119726)
4. Mortz CG, Andersen KE: Allergic contact dermatitis in children and adolescents. Contact Dermatitis 1999, 41:121-130. (Pubitemid 29405590)
5. Devillers AC, Oranje AP: Efficacy and safety of 'wet-wrap' dressings as an intervention treatment in children with severe and/or refractory atopic dermatitis: a critical review of the literature.. Br J Dermatol 2006, 154:579-585. (Pubitemid 43374079)
6. Schnopp C, Holtmann C, Stock S, Remling R, Fölster-Holst R, Ring J, Abeck D: Topical steroids under wet-wrap dressings in atopic dermatitis-a vehicle-controlled trial. Dermatology 2002, 204:56-59. (Pubitemid 34136815)
7. Wollenberg A, Bieber T: Proactive therapy of atopic dermatitis -an emerging concept. Allergy 2009, 64:276-278.
8. Van Der Meer JB, Glazenburg EJ, Mulder PG, Eggink HF, Coenraads PJ: The management of moderate to severe atopic dermatitis in adults with topical fluticasone propionate. The Netherlands Adult Atopic Dermatitis Study Group. Br J Dermatol 1999, 140:1114-1121. (Pubitemid 29284586)
9. Feiwel M, Munro D, James V: Effect of topically applied 0.1% betamethasone valerate ointment on the adrenal function of children.. In Thirteenth congress of International Dermatology. Berlin: Springer; 1968:202-204.
10. Walsh P, Aeling J, Huff L, Weston W: Hypothalamus-pituitary-adrenal axis suppression by superpotent topical steroids. J Am Acad Dermatol 1993, 29:501-503. (Pubitemid 23260151)
11. Bornhövd E, Burgdorf W H C, Wollenberg A: Macrolactam immunomodulators for topical treatment of inflammatory skin diseases. J Am Acad Dermatol 2001, 45:736-743. (Pubitemid 33032572)
12. Ruzicka T, Bieber T, Schöpf E, Rubins A, Dobozy A, Bos J, et al: A short-term trial of tacrolimus ointment for atopic dermatitis. N Engl J Med 1997, 337:816-821. (Pubitemid 27391631)
13. Van Leent EJ, Graber M, Thurston M, Wagenaar A, Spuls PI, Bos JD: Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis.. Arch Dermatol 1998, 134:805-809. (Pubitemid 28350183)
14. Reitamo S, Wollenberg A, Schöpf E, Perrot JL, Marks R, Ruzicka T, et al: Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. Arch Dermatol 2000, 136:999-1006. (Pubitemid 30629127)
15. Meurer M, Fölster-Holst R, Wozel G, Weidinger G, Jünger M, Bräutigam M: Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. Dermatology 2002, 205:271-277.
16. Wollenberg A, Reitamo S, Girolomoni G, Lahfa M, Ruzicka T, Healy E, Giannetti A, Bieber T, Vyas J, Deleuran M: Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment. Allergy 2008, 63:742-750.
17. Thaci D, Reitamo S, Gonzalez Ensenat MA, Moss C, Boccaletti V, Cainelli T, Van Der Valk P, Buckova H, Sebastian M, Schuttelaar M, Ruzicka T: Proactive disease management with 0.03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study.. Br J Dermatol 2008, 159:1348-1356.
18. Reitamo S, Rustin M, Ruzicka T, Cambazard F, Kalimo K, Friedmann P, et al: Efficacy and safety of tacrolimus ointment compared with hydrocortisone butyrate ointment in adult patients with atopic dermatitis.. J Allergy Clin Immunol 2002, 109:547-555. (Pubitemid 34234209)
19. Luger T, Van Leent E, Graeber M, Hedgecock S, Thurston M, Kandra A, et al: SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. Br J Dermatol 2001, 144:788-794. (Pubitemid 32374782)
20. Diepgen TL: Long-term treatment with cetirizine of infants with atopic dermatitis: a multi-country, double-blind, randomized, placebocontrolled trial (the ETAC trial) over 18 months.. Pediatr Allergy Immunol 2002, 13:278-286. (Pubitemid 35231044)
21. De Benedetto A, Agnihothri R, McGirt LY, Bankova LG, Beck LA: Atopic dermatitis: a disease caused by innate immune defects. J Invest Dermatol 2009, 129:14-30-22.
22. Lübbe J: Secondary infections in patients with atopic dermatitis. Am J Clin Dermatol 2003, 4:641-654. (Pubitemid 37108422)
23. Shah M, Mohanraj M: High levels of fusidic acid resistant Staphylococcus aureus in dermatology patients. Br J Dermatol 2003, 148:1018-1020. (Pubitemid 36750797)
24. Niebuhr M, Mai U, Kapp A, Werfel T: Antibiotic treatment of cutaneous infections with Staphylococcus aureus in patients with atopic dermatitis: current antimicrobial resistances and susceptibilities.. Exp Dermatol 2008, 17:953-957.
25. Bunikowski R, Mielke M, Skarabis H, Worm M, Anagnostopoulos I, Kolde G, et al: Evidence for a disease-promoting effect of staphylococcus aureus-derived exotoxins in atopic dermatitis.. J Allergy Clin Immunol 2000, 105:814-819. (Pubitemid 30226458)
26. Zollner T, Wichelhaus T, Hartung A, Von Mallinckrodt C, Wagner T, Brade V, et al: Colonization with superantigen-producing staphylococcus aureus is associated with increased severity of atopic dermatitis.. Clin Exp Allergy 2000, 30:994-1000. (Pubitemid 30427041)
27. Hauser C, Wuethrich B, Matter L: Staphylococcus aureus skin colonization in atopic dermatitis. Dermatologica Helvetica 1985, 170:35.
28. Breuer K, Haussler S, Kapp A, Werfel T: Staphylococcus aureus: colonizing features and influence of an antibacterial treatment in adults with atopic dermatitis.. Br J Dermatol 2002, 147:55-61. (Pubitemid 34779438)
29. Lintu P, Savolainen J, Kortekangas-Savolainen O, Kalimo K: Systemic ketoconazole is an effective treatment of atopic dermatitis with IgE-mediated hypersensitivity to yeasts.. Allergy 2001, 56:512-517. (Pubitemid 32521431)
30. Mayser P, Kupfer J, Nemetz D, Schäfer U, Nilles M, Hort W, Gieler U: Treatment of head and neck dermatitis with ciclopiroxolamine cream - results of a double-blind, placebo-controlled study.. Skin Pharmacol Physiol 2006, 19:153-158.
31. Williams HC, Grindlay DJ: What's new in atopic eczema? An analysis of the clinical significance of systematic reviews on atopic eczema published in 2006 and 2007.. Clin Exp Dermatol 2008, 33:685-688.
32. Akhavan A, Rudikoff D: Atopic dermatitis: systematic immunosuppressive therapy. Semin Cutan Med Surg 2008, 27:151-155. (Pubitemid 351938751)
33. Berth-Jones L, Finlay A, Zaki I, Tan B, Goodyear H, Lewis-Jones S, et al: Ciclosporin in severe childhood atopic dermatitis: a multicentre study. J Am Acad Dermatol 1996, 34:1016-1021. (Pubitemid 26170768)
34. Van Joost T, Heule F, Korstanje M, Van-den-Broek M, Stenveld H, Van-Vloten W: Ciclosporin in atopic dermatitis: a multicentre, placebo-controlled study. Br J Dermatol 1994, 130:634-640. (Pubitemid 24204701)
35. Murphy LA, Atherton D: A retrospective evaluation of azathioprine in severe childhood atopic eczema, using thiopurine methyltransferase levels to exclude patients at high risk of myelosuppression.. Br J Dermatol 2002, 147:308-315.
36. Berth-Jones J, Takwale A, Tan E, Barclay G, Agarwal S, Ahmed I, et al: Azathioprine in severe adult atopic dermatitis: a double-blind, placebocontrolled, crossover trial.. Br J Dermatol 2002, 147:324-330.
37. Grundmann-Kollmann M, Podda M, Ochsendorf F, Boehncke W-H, Kaufmann R, Zollner T: Mycophenolate mofetil is effective in the treatment of atopic dermatitis. Arch Dermatol 2001, 137:870-873. (Pubitemid 32641646)
38. Heller M, Shin HT, Orlow SJ, Schaffer JV: Mycophenolate mofetil for severe childhood atopic dermatitis: experience in 14 patients. Br J Dermatol 2007, 157:127-132. (Pubitemid 46934265)
39. Murray ML, Cohen JB: Mycophenolate mofetil therapy for moderate to severe atopic dermatitis. Clin Exp Dermatol 2007, 32:23-27. (Pubitemid 46006360)
40. Goujon C, Berard F, Dahel K, Guillot I, Hennino A, Nosbaum A, Saad N, Nicolas JF: Methotrexate for the treatment of adult atopic dermatitis. Eur J Dermatol 2006, 16:155-158.
41. Simon D, Wittwer J, Kostylina G, Buettiker U, Simon HU, Yawalkar N: Alefacept (lymphocyte function-associated molecule 3/IgG fusion protein) treatment for atopic eczema.. J Allergy Clin Immunol 2008, 122:423-424.
42. Moul DK, Routhouska SB, Robinson MR, Korman NJ: Alefacept for moderate to severe atopic dermatitis: a pilot study in adults. J Am Acad Dermatol 2008, 58:984-989.
43. Simon D, Hösli S, Kostylina G, Yawalkar N, Simon HU: Anti-CD20 (rituximab) treatment improves atopic eczema. J Allergy Clin Immunol 2008, 121:122-128.
44. Darsow U, Wollenberg A, Simon D, Taïeb A, Werfel T, Oranje A, Gelmetti C, Svensson A, Deleuran M, Calza AM, Giusti F, Lübbe J, Seidenari S, Ring J for the European Task Force on Atopic Dermatitis/EADV Eczema Task Force: ETFAD/EADV Eczema Task Force 2009 position paper on diagnosis and treatment of atopic dermatitis. J Eur Acad Dermatol Venereol 2010, 24:317-328.
45. Staab D, Diepgen TL, Fartasch M, Kupfer J, Lob-Corzilius T, Ring J, et al: Age related, structured educational programmes for the management of atopic dermatitis in children and adolescents: multicentre, randomised controlled trial.. BMJ 2006, 332:933-938.